# Cardiff Oncology, Inc.: financial statements, quarterly

CRDF · Nasdaq · CIK 1213037 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/crdf.md) · [Financials](/companies/crdf/financials.md) · [Filings](/companies/crdf/filings.md) · [Insiders](/companies/crdf/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/crdf/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.1](/filings/0000950170-24-123242.md) | [0.2 d](/filings/0000950170-25-028992.md) | [0.2](/filings/0000950170-25-066886.md) | [0.2](/filings/0000950170-25-099610.md) | [0.2](/filings/0001193125-25-269424.md) | [0.2 d](/filings/0001193125-26-067464.md) | [0.1](/filings/0001213037-26-000011.md) | [0.1](/filings/0001193125-26-344545.md) | [0.1](/filings/0001193125-25-269424.md) | [0.2 d](/filings/0001193125-26-067464.md) | [0.0](/filings/0001213037-26-000011.md) | [0.1](/filings/0001193125-26-344545.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $m | [2.9](/filings/0000950170-24-123242.md) | [2.7 d](/filings/0000950170-25-028992.md) | [3.1](/filings/0000950170-25-066886.md) | [3.2](/filings/0000950170-25-099610.md) | [3.1](/filings/0001193125-25-269424.md) | [3.0 d](/filings/0001193125-26-067464.md) | [4.0](/filings/0001213037-26-000011.md) | [3.3](/filings/0001193125-26-344545.md) | [3.9](/filings/0001193125-25-269424.md) | [3.0 d](/filings/0001193125-26-067464.md) | [6.1](/filings/0001213037-26-000011.md) | [3.8](/filings/0001193125-26-344545.md) |
| Operating income | $m | [(10.8)](/filings/0000950170-24-123242.md) | [(10.3) d](/filings/0000950170-25-028992.md) | [(10.9)](/filings/0000950170-25-066886.md) | [(12.5)](/filings/0000950170-25-099610.md) | [(12.6)](/filings/0001193125-25-269424.md) | [(12.6) d](/filings/0001193125-26-067464.md) | [(14.4)](/filings/0001213037-26-000011.md) | [(14.8)](/filings/0001193125-26-344545.md) | [(12.0)](/filings/0001193125-25-269424.md) | [(7.8) d](/filings/0001193125-26-067464.md) | [(12.9)](/filings/0001213037-26-000011.md) | [(9.6)](/filings/0001193125-26-344545.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(9.7)](/filings/0000950170-24-123242.md) | [(9.3) d](/filings/0000950170-25-028992.md) | [(10.0)](/filings/0001193125-25-269424.md) | [(11.8)](/filings/0001193125-25-269424.md) | [(11.9)](/filings/0001193125-25-269424.md) | [(11.8) d](/filings/0001193125-26-067464.md) | [(13.4)](/filings/0001193125-26-344545.md) | [(13.9)](/filings/0001193125-26-344545.md) | [(11.3)](/filings/0001193125-25-269424.md) | [(7.2) d](/filings/0001193125-26-067464.md) | [(12.3)](/filings/0001193125-26-344545.md) | [(9.2)](/filings/0001193125-26-344545.md) |
| Diluted EPS | $ per share | [(0.22)](/filings/0000950170-24-123242.md) | not reported | [(0.22)](/filings/0000950170-25-066886.md) | [(0.26)](/filings/0000950170-25-099610.md) | [(0.25)](/filings/0001193125-25-269424.md) | not reported | [(0.20)](/filings/0001213037-26-000011.md) | [(0.21)](/filings/0001193125-26-344545.md) | [(0.17)](/filings/0001193125-25-269424.md) | not reported | [(0.18)](/filings/0001213037-26-000011.md) | [(0.14)](/filings/0001193125-26-344545.md) |
| Basic EPS | $ per share | [(0.22)](/filings/0000950170-24-123242.md) | not reported | [(0.22)](/filings/0000950170-25-066886.md) | [(0.26)](/filings/0000950170-25-099610.md) | [(0.25)](/filings/0001193125-25-269424.md) | not reported | [(0.20)](/filings/0001213037-26-000011.md) | [(0.21)](/filings/0001193125-26-344545.md) | [(0.17)](/filings/0001193125-25-269424.md) | not reported | [(0.18)](/filings/0001213037-26-000011.md) | [(0.14)](/filings/0001193125-26-344545.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: not reported
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [15.2](/filings/0001628280-23-036375.md) | [21.7](/filings/0000950170-25-028992.md) | [18.7](/filings/0001628280-24-019974.md) | [25.5](/filings/0001628280-24-036098.md) | [13.0](/filings/0000950170-24-123242.md) | [51.5](/filings/0001193125-26-067464.md) | [24.1](/filings/0000950170-25-066886.md) | [10.8](/filings/0000950170-25-099610.md) | [10.1](/filings/0001193125-25-269424.md) | [17.5](/filings/0001193125-26-344545.md) | [8.5](/filings/0001213037-26-000011.md) | [9.2](/filings/0001193125-26-344545.md) |
| Current assets | $m | [83.9](/filings/0001628280-23-036375.md) | [77.4](/filings/0000950170-25-028992.md) | [70.0](/filings/0001628280-24-019974.md) | [62.2](/filings/0001628280-24-036098.md) | [59.3](/filings/0000950170-24-123242.md) | [95.1](/filings/0001193125-26-067464.md) | [82.7](/filings/0000950170-25-066886.md) | [73.7](/filings/0000950170-25-099610.md) | [61.8](/filings/0001193125-25-269424.md) | [60.1](/filings/0001193125-26-344545.md) | [47.3](/filings/0001213037-26-000011.md) | [35.6](/filings/0001193125-26-344545.md) |
| Total assets | $m | [88.5](/filings/0001628280-23-036375.md) | [81.6](/filings/0000950170-25-028992.md) | [74.0](/filings/0001628280-24-019974.md) | [66.1](/filings/0001628280-24-036098.md) | [62.9](/filings/0000950170-24-123242.md) | [97.2](/filings/0001193125-26-067464.md) | [84.8](/filings/0000950170-25-066886.md) | [75.7](/filings/0000950170-25-099610.md) | [63.8](/filings/0001193125-25-269424.md) | [61.9](/filings/0001193125-26-344545.md) | [49.2](/filings/0001213037-26-000011.md) | [37.3](/filings/0001193125-26-344545.md) |
| Current liabilities | $m | [9.0](/filings/0001628280-23-036375.md) | [10.4](/filings/0000950170-25-028992.md) | [11.8](/filings/0001628280-24-019974.md) | [12.5](/filings/0001628280-24-036098.md) | [12.5](/filings/0000950170-24-123242.md) | [13.4](/filings/0001193125-26-067464.md) | [13.3](/filings/0000950170-25-066886.md) | [16.7](/filings/0000950170-25-099610.md) | [14.7](/filings/0001193125-25-269424.md) | [16.4](/filings/0001193125-26-344545.md) | [14.5](/filings/0001213037-26-000011.md) | [10.8](/filings/0001193125-26-344545.md) |
| Total liabilities | $m | [10.6](/filings/0001628280-23-036375.md) | [11.9](/filings/0000950170-25-028992.md) | [13.1](/filings/0001628280-24-019974.md) | [13.7](/filings/0001628280-24-036098.md) | [13.5](/filings/0000950170-24-123242.md) | [14.2](/filings/0001193125-26-067464.md) | [13.9](/filings/0000950170-25-066886.md) | [17.1](/filings/0000950170-25-099610.md) | [15.0](/filings/0001193125-25-269424.md) | [16.5](/filings/0001193125-26-344545.md) | [14.5](/filings/0001213037-26-000011.md) | [10.8](/filings/0001193125-26-344545.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [77.8](/filings/0000950170-24-123242.md) | [69.7](/filings/0001193125-26-067464.md) | [60.9](/filings/0001193125-25-269424.md) | [52.4](/filings/0001193125-25-269424.md) | [49.4](/filings/0001193125-25-269424.md) | [82.9](/filings/0001193125-26-344545.md) | [70.9](/filings/0001193125-26-344545.md) | [58.6](/filings/0001193125-26-344545.md) | [48.8](/filings/0001193125-25-269424.md) | [45.4](/filings/0001193125-26-344545.md) | [34.7](/filings/0001193125-26-344545.md) | [26.5](/filings/0001193125-26-344545.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(8.0) d](/filings/0000950170-24-123242.md) | [(7.1) d](/filings/0000950170-25-028992.md) | [(7.7)](/filings/0000950170-25-066886.md) | [(9.2) d](/filings/0000950170-25-099610.md) | [(10.5) d](/filings/0001193125-25-269424.md) | [(10.3) d](/filings/0001193125-26-067464.md) | [(12.8)](/filings/0001213037-26-000011.md) | [(8.3) d](/filings/0001193125-26-344545.md) | [(10.8) d](/filings/0001193125-25-269424.md) | [(6.0) d](/filings/0001193125-26-067464.md) | [(12.3)](/filings/0001213037-26-000011.md) | [(11.8) d](/filings/0001193125-26-344545.md) |
| Capital expenditure | $m | [0.3 d](/filings/0000950170-24-123242.md) | [0.0 d](/filings/0000950170-25-028992.md) | [0.1](/filings/0000950170-25-066886.md) | [0.0 d](/filings/0000950170-25-099610.md) | [0.0 d](/filings/0001193125-25-269424.md) | [0.0 d](/filings/0001193125-26-067464.md) | not reported | not reported | [0.0 d](/filings/0001193125-25-269424.md) | [0.0 d](/filings/0001193125-26-067464.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [43.3](/filings/0001628280-23-036375.md) | [44.7](/filings/0001628280-24-019974.md) | [44.7](/filings/0001628280-24-036098.md) | [44.7](/filings/0000950170-24-123242.md) | [44.7](/filings/0000950170-25-066886.md) | [44.8](/filings/0000950170-25-099610.md) | [46.9](/filings/0001193125-25-269424.md) | [66.5](/filings/0001213037-26-000011.md) | [66.5](/filings/0001193125-26-344545.md) | [66.9](/filings/0001193125-25-269424.md) | [68.4](/filings/0001213037-26-000011.md) | [68.4](/filings/0001193125-26-344545.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 77,795,249 at 2026-08-06, from the cover of the [10-Q filed 2026-08-11](/filings/0001193125-26-344545.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:35 ET. No prices; not investment advice.
